Phage display-derived cross-reactive neutralizing antibody against enterovirus 71 and coxsackievirus A16

Japanese Journal of Infectious Diseases

Volumn 69, Issue 1, 2016, Pages 66-74

  Zhang, Xiao ^a   Sun, Chunyun ^b   Xiao, Xiangqian ^a   Pang, Lin ^c   Shen, Sisi ^a   Zhang, Jie ^b   Cen, Shan ^d   Yang, Burton B ^e   Huang, Yuming ^c   Sheng, Wang ^a   Zeng, Yi ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BIOPANNING; CONTROLLED STUDY; COXSACKIEVIRUS A16; ENTEROVIRUS 71; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PHAGE DISPLAY; POLYMERASE CHAIN REACTION; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CROSS REACTION; ENTEROVIRUS; ENTEROVIRUS A; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; PEPTIDE LIBRARY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; FEMALE; MICE, INBRED BALB C; PEPTIDE LIBRARY;

EID: 84955116201     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.JJID.2015.060     Document Type: Article

References (39)

1. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304-9.
2. Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39: 195-205.
3. Tuthill T, Groppelli E, Hogle J, et al. Picornaviruses. In: Johnson JE editor. Cell Entry by Non-Enveloped Viruses. Berlin: Springer Berlin Heidelberg; 2010. p. 43-89.
4. Wang X, Peng W, Ren J, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424-9.
5. Chow M, Newman JF, Filman D, et al. Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature. 1987;327:482-6.
6. Ren J, Wang X, Hu Z, et al. Picornavirus uncoating intermediate captured in atomic detail. Nat Commun. 2013;4:1929.
7. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91-107.
8. Yen FB, Chang LY, Kao CL, et al. Coxsackieviruses infection in northern Taiwan–epidemiology and clinical characteristics. J Microbiol Immunol Infect. 2009;42:38-46.
9. Suzuki Y, Taya K, Nakashima K, et al. Risk factors for severe hand foot and mouth disease. Pediatr Int. 2010;52:203-7.
10. Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14: e1076-81.
11. Chen KT, Chang HL, Wang ST, et al. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics. 2007;120:e244-52.
12. Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778-90.
13. Yan XF, Gao S, Xia JF, et al. Epidemic characteristics of hand, foot, and mouth disease in Shanghai from 2009 to 2010: Enterovirus 71 subgenotype C4 as the primary causative agent and a high incidence of mixed infections with coxsackievirus A16. Scand J Infect Dis. 2012;44:297-305.
14. Zhao K, Han X, Wang G, et al. Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis. 2011;17:1537-40.
15. Li Y, Zhu R, Qian Y, et al. Comparing Enterovirus 71 with Coxsackievirus A16 by analyzing nucleotide sequences and antigenicity of recombinant proteins of VP1s and VP4s. BMC Microbiol. 2011;11:246.
16. Wu CN, Lin YC, Fann C, et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20: 895-904.
17. Li J, Chang J, Liu X, et al. Protection from lethal challenge in a nenonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol. 2014;95: 1083-93.
18. Foo DG, Alonso S, Chow VT, et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007; 9:1299-306.
19. Lim XF, Jia Q, Khong WX, et al. Characterization of an isotype dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012;7:e29751.
20. Xu L, He D, Li Z, et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing eitope within the VP2 EF loop. Theranostics. 2014;4:498-513.
21. Kiener TK, Jia Q, Meng T, et al. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved ``knob'' region of VP3 protein. PLoS Negl Trop Dis. 2014;8:e2895.
22. Zhao M, Bai Y, Liu W, et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol. 2013;13:287.
23. Zhou H, Fisher RJ, Papas TS. Optimization of primer sequences for mouse scFv repertoire display library construction. Nucleic Acids Res. 1994;22:888-9.
24. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991;222:581-97.
25. Clark MA, Hawkins NJ, Papaioannou A, et al. Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library. Clin Exp Immunol. 1997;109:166-74.
26. Coomber DWJ, Hawkins NJ, Clark MA, et al. Generation of anti- p53 Fab fragments from individuals with colorectal cancer using phage display. J Immunol. 1999;163:2276-83.
27. Makvandi-Nejad S, Sheedy C, Veldhuis L, et al. Selection of single chain variable fragment (scFv) antibodies from a hyperimmunized phage display library for the detection of the antibiotic monensin. J Immunol Methods. 2010;360:103-18.
28. Zhang JL, Gou JJ, Zhang ZY, et al. Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen. Hepatobiliary Pancreat Dis Int. 2006;5: 237-41.
29. He FT, Nie YZ, Chen BJ, et al. Expression and identification of recombinant soluble single-chain variable fragment of monoclonal antibody MC3. World J Gastroenterol. 2002;8:258-62.
30. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv. 2010;28: 849-58.
31. Liu CC, Guo MS, Lin FH, et al. Purification and characterization of enterovirus 71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011; 6:e20005.
32. Chong P, Guo MS, Lin FH, et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS One. 2012;7:e49973.
33. Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol. 1990;64:1934-45.
34. Greve JM, Forte CP, Marlor CW, et al. Mechanisms of receptormediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol. 1991;65:6015-23.
35. Katpally U, Fu TM, Freed DC, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83:7040-8.
36. Casson LP, Manser T. Evaluation of loss and change of specificity resulting from random mutagenesis of an antibody VH region. J Immunol. 1995;155:5647-54.
37. Kobayashi N, Oyama H, Kato Y, et al. Two-step in vitro antibody affinity maturation enables estradiol-1b assays with more than 10-fold higher sensitivity. Anal Chem. 2010;82:1027-38.
38. Babcook JS, Leslie KB, Olsen OA, et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA. 1996;93:7843-8.
39. Li Z, Xu L, He D, et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One. 2014;9: e109391.